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Abstract: The synthesis, cytotoxicity and inhibition of CDK8 by thirteen analogs of cortistatin A are
reported. These efforts revealed that the analogs with either a 6- or 7-isoquinoline or 5-indole side
chain in the 17-position are the most promising anti-proliferative agents. These compounds showed
potent cytotoxic effects in CEM, HeLa and HMEC-1 cells. All three compounds exhibited IC50 values
< 10µM. The most interesting 10l analog exhibited an IC50 value of 0.59 µM towards the human
dermal microvascular endothelial cell line (HMEC-1), significantly lower than the reference standard
2-methoxyestradiol. At a concentration at 50 nM the most potent 10h compound reduced the activity
of CDK8 to 35%.
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1. Introduction
Steroids are a class of biologically active molecules, important for an array of different physiological
effects. Their affinities for various types of nuclear receptors, as well as their safe pharmacological profile
have facilitated their widespread application in drug discovery and development [1]. Over recent years,
an extensive focus on chemical modification of the steroidal structure has been seen. Such modifications
of the steroidal nucleus have yielded several important anticancer molecules and lead compounds.
Exemestane (1), [2] abiraterone (2) [3,4] and 2-methoxyestradiol (2-ME) (3) [5,6] are some of the
successful examples that have emerged from steroidal pharmacophores, see Figure 1.
A class of compound, the cortistatins, exemplified by cortistatins A (4), see Figure 1, are examples
of natural occurring steroid-like structures that have attracted great interest within anti-cancer
research [7,8]. In 2006, cortistatin A (4) was the first compound of this group of steroidal-like alkaloids
to be isolated from the marine sponge Corticium simplex [9]. The compound was later synthesized, and
thoroughly evaluated for its biological effects [10–13]. Cortistatin A (4) exhibits potent anti-angiogenetic
effects, proved by the inhibition of the proliferation of human umbilical vein endothelial cells (HUVECs)
in the low nano-molar range [14]. Moreover, cortistatin A (4) is reported to have anti-leukemic activity
in vitro and in vivo, and disproportionately induces upregulation of SE-associated genes in CA-sensitive
AML cell lines [12]. In addition, several analogs of 5 with interesting anti-cancer effects have been
prepared [6–8,15–17]. Structure-activity-relationship (SAR)-studies have revealed the presence of an
isoquinoline group to be crucial for the activity and that the two hydroxyl-groups on the A ring are
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removable. Along these lines, one of the most interesting analogs reported so far is the amino steroid 5
reported by Corey and co-workers [7].
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Figure 1. Chemical structures of biological active steroidal compounds. 
Herein we present our aim to investigate the biological effects of introducing a variety of 
nitrogen containing heterocycle systems, inspired by the above mentioned compounds, at the 17-
position of didehydroepiandrosterone (DHEA) (6). 
2. Results  
2.1. Chemistry 
The analogs 10a–10m were prepared as depicted in Scheme 1. First, DHEA (6) was converted to 
the TBS-protected ketone 7. Then the enol-triflate 8 was made from the ketone 7 in a reaction using 
N-phenyl-bis(trifluoromethanesulfonimide) in the presence of KHMDS at −78 °C. This sequence 
afforded compound 8 in 85% yield from dehydroepiandrosterone (6). Then compound 8 was 
employed in a Suzuki Miyaura reaction with different commercially available boronic acids. In the 
presence of Pd(PPh3)4 and Cs2CO3 in THF/H2O (1:1), the TBS protected compounds 9a–9m were 
obtained (Scheme 1). Of note, the Suzuki Miyaura reaction with the chlorinated analogs (9c and 9e) 
proved troublesome, due to the observation of polymerization of the chlorinated boronic acid. The 
polymeric material was hard to remove during work up, but by slowly adding a solution of the 
boronic acid in THF to the stirred reaction mixture, we managed to reduce the amount of polymeric 
material and isolate the desired compounds in decent yield (see Supporting Information). The desired 
analogs, 10a–10m, were obtained after removal of the TBS-group under standard conditions using 
TBAF in THF. 
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i we present our aim to investigate th biological effects of introducing a variety of nitrogen
containing heterocycle systems, inspired by the above m nti n d compounds, at the 17-position of
didehydr epiandrosterone (DHEA) (6).
2. Results
2.1. Chemistry
The analogs 10a–10m were prepared as depicted in Scheme 1. First, DHEA (6) was converted
to the TBS-protected ketone 7. Then the enol-triflate 8 was made from the ketone 7 in a reaction
using N-phenyl-bis(trifluoromethanesulfonimide) in the presence of KHMDS at −78 ◦C. This sequence
afforded compound 8 in 85% yield from dehydroepiandrosterone (6). Then compound 8 was employed
in a Suzuki Miyaura reaction with different commercially available boronic acids. In the presence
of Pd(PPh3)4 and Cs2CO3 in THF/H2O (1:1), the TBS protected compounds 9a–9m were obtained
(Scheme 1). Of note, the Suzuki Miyaura reaction with the chlorinated analogs (9c and 9e) proved
troublesome, due to the observation of polymerization of the chlorinated boronic acid. The polymeric
material was hard to remove during work up, but by slowly adding a solution of the boronic acid in
THF to the stirred reaction mixture, we managed to reduce the amount of polymeric material and
isolate the desired compounds in decent yield (see Supporting Information). The desired analogs,
10a–10m, were obtained after removal of the TBS-group under standard conditions using TBAF in THF.
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Scheme 1. Synthesis of compounds 10a–10m. Reagents and conditions: (i) TBSCl, imidazole, DMF rt., 
5h, 96% (ii) KHMDS, PhN(SO2CF3)2, THF, −78 °C, 4 h, 89%; (iii) ArB(OH)2, Cs2CO3, Pd(Ph3P)4, 
THF:H2O (1:1) 60 °C, 5 h, 53–88%; (iv) TBAF, THF, rt., 41–89%. 
2.2. Biological Evaluation 
The prepared steroidal analogues 10a–10m were evaluated, together with 2-ME (3), for their 
antiproliferative effects in two different cancer cell lines, human T-cell leukemia (CEM) and human 
cervix carcinoma (HeLa) as well as the human dermal microvascular endothelial cell-line HMEC-1. 
The data are expressed as IC50 (50% inhibitory concentration), which is defined as the compound 
concentration that reduces cell proliferation by 50%, and are shown in Table 1. The reference 
compound 2-ME (3) inhibited the growth of all cell lines tested in the low micromolar range (IC50 
between 0.4 and 1.6 µM). Among the prepared analogues, the most potent compound proved to be 
the indole-5-yl analogue of DHEA (10l), with IC50 values of 1.5 ± 0.2 and 2.9 ± 1.0 µM towards the 
CEM and HeLa cell lines, respectively. Furthermore, the same compound showed potent inhibition 
of endothelial cell growth with an IC50 value of 0.59 ± 0.07 µM. The corresponding value of 2-ME (3) 
was 1.3 ± 0.5, which proved that compound 10l was significantly more potent compared towards the 
HMEC-1 cell line. Unfortunately, among the other compounds the cytotoxic properties were either 
poor compared to the 2-ME (3) or not present at all.  
Table 1. Biological evaluation of compounds 10a–10m. 
Compound 
CEM 
Cell Assay  
IC50 (µM) a 
HeLa 
Cell Assay  
IC50 (µM) a 
HMEC-1 
Cell Assay  
IC50 (µM) a 
CDK8  
Per Cent of 
Control (POC)  
10a >100 >100 >100 n.d. b 
10b 16 ± 3 90 ± 14 17 ± 4 n.d. 
10c 18 ± 4 97 ± 4 60 ± 4 95% 
10d >100 2.1 ± 1.7 88 ± 8 n.d. 
10e 10 ± 1 18 ± 11 8.2 ± 1.9 100% 
10f 24 ± 16 7.0 ± 2.5 11 ± 1 n.d. 
10g 14 ± 1 24 ± 6 15 ± 0 n.d. 
Scheme 1. Synthesis of compounds 10a–10m. Reagents and conditions: (i) TBSCl, imidazole, DMF
rt., 5h, 96% (ii) KHMDS, PhN(SO2CF3)2, THF, −78 ◦C, 4 h, 89%; (iii) ArB(OH)2, Cs2CO3, Pd(Ph3P)4,
THF:H2O (1:1) 60 ◦C, 5 h, 53–88%; (iv) TBAF, THF, rt., 41–89%.
2.2. iol i l
The pre are st i r al ated, together with 2-ME (3), for their
antiprolifer ti ff ff ll i s, an T-ce l leukemia (CEM) and human
cervix carci ( al icrovascular endothelial cel -line HMEC-1.
The data are expresse as I 50 r centration), which is defined as the compound
concentration that reduces cell proliferation by 50%, and are shown in Table 1. he referenc compound
2-ME (3) inhibited the growth of all cell lines test d in the low micromolar range (IC50 between 0.4
and 1.6 µM). Among the prepared analogues, the most potent compound proved to be the indole-5-yl
analogue of DHEA (10l), with IC50 values of 1.5 ± 0.2 and 2.9 ± 1.0 µM towards the CEM an HeLa
cell lines, respectively. Furthermore, the same compound showed potent inhibition of endothelial cell
growth with an IC50 value of 0.59 ± 0.07 µM. The corresponding value of 2-ME (3) was 1.3 ± 0.5, which
proved that compound 10l was significantly more potent compared towards the HMEC-1 cell line.
Unfortunately, among the other compounds the cytotoxic properties were either poor compared to the
2-ME (3) or not present at all.
Inspired by the potent inhibitory activity of cortistatin A (4) towards CDK8, we decided to submit
seven of the compounds to a CDK8 inhibition assay. The compounds were tested for their ability to
inhibit probe binding to protein kinase CDK8 in vitro at 50 nM concentration. In this assay, the ability
of a test compound to compete with an immobilized, active site directed ligand is qua titatively
measured and reported as percent of DMSO control (POC), with lower numbers indicating higher
binding affinity. The results are displayed in Table 1. Unfortunately, from the results obtained in this
assay no correlation between the cytotoxicity of the compounds and their ability to inhibit CDK8 can be
seen. The only compound with some probe-binding inhibition properties of CDK8 was compound 10h.
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10a >100 >100 >100 n.d. b
10b 16 ± 3 90 ± 14 17 ± 4 n.d.
10c 18 ± 4 97 ± 4 60 ± 4 95%
10d >100 2.1 ± 1.7 88 ± 8 n.d.
10e 10 ± 1 18 ± 11 8.2 ± 1.9 100%
10f 24 ± 16 7.0 ± 2.5 11 ± 1 n.d.
10g 14 ± 1 24 ± 6 15 ± 0 n.d.
10h 16 ± 2 24 ± 8 13 ± 0 32%
10i 5.4 ± 0.6 9.2 ± 0.9 2.6 ± 0.4 100%
10j 5.8 ± 3.1 8.7 ± 0.0 5.4 ± 3.6 100%
10k 26 ± 17 91 ± 12 8.4 ± 4.3 100%
10l 1.5 ± 0.2 2.9 ± 1.0 0.59 ± 0.07 100%
10m 50 ± 21 44 ± 2 14 ± 2 n.d.
2-ME (3) 1.6 ± 0.9 0.41 ± 0.06 1.3 ± 0.5 n.d.
a Results of three experiments performed as triplicates, b n.d = not determined.
3. Materials and Methods
3.1. Chemistry
3.1.1. General Methods
All reagents and solvents were used as purchased without further purification unless stated
otherwise. Melting points are uncorrected. Analytical TLC was performed using silica gel 60 F254
aluminum plates (Merck). Flash column chromatography was performed on silica gel 60 (40–63 mm)
produced by Merck. NMR spectra were recorded on a Bruker Avance DPX-300 MHz or DPX-400
MHz spectrometer for 1H-NMR, and 75 MHz or 101 MHz for 13C-NMR. Coupling constants (J) are
reported in Hertz, and chemical shifts are reported in parts per million relative to CDCl3 (7.26 ppm
for 1H and 77.0 ppm for 13C). Mass spectra were recorded at 70 eV with Fison’s VG Pro spectrometer.
High-resolution mass spectra were performed with a VG Prospecmass spectrometer and with a
Micromass Q-TOF-2™. Protocols for the preparation, physical and spectral data of the intermediates 7,
8 and 9a–9m are presented in the supplementary materials.
3.1.2. A General Procedure for the Deprotection
The TBS protected steroids 9a–9m (0.15–0.2 mmol, 1 equiv.) were placed in a dry round-bottomed
flask under an argon atmosphere, and dissolved in dry THF (3–4 mL). Tert-butylammoniumfluoride
(1 M in THF, 1.1 equiv.) was added dropwise. The reaction mixture was stirred at room temperature
(16–18 h). Upon completion, the reaction the mixture was poured into saturated aqueous NaHCO3
(10 mL), and extracted with ethyl acetate (4 × 5 mL). The combined organic extracts were dried (MgSO4)
and the solvent evaporated in vacuo. The residues were purified by chromatography (silica gel, 20–50%
ethyl acetate in hexane) to give the pure products. The reactions performed were followed by TLC,
using cerium ammonium molybdate (CAM) stain to visualize the spots.
(8R,9S,10R,13S,14S)-10,13-Dimethyl-17-phenyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]
phenanthren-3-ol (10a). Colorless solid (61 mg, 87%). Purified by column chromatography on silica
gel using 20% ethyl acetate in heptane as eluent. Rf = 0.43 (20% ethyl acetate in heptane). 1H NMR
(400 MHz, CDCl3) δ 7.37–7.32 (m, 2H), 7.29–7.15 (m, 3H), 6.00–5.68 (m, 1H), 5.50–5.22 (m, 1H), 3.64–3.36
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(m, 1H), 2.37–2.14 (m, 3H), 2.12–1.95 (m, 3H), 1.88–1.38 (m, 9H), 1.12–0.99 (m, 8H), 0.89–0.82 (m, 1H).
13C NMR (101 MHz, CDCl3) δ 154.95, 141.27, 137.48, 128.22, 127.32, 126.83, 121.61, 71.90, 57.84, 50.61,
47.37, 42.49, 37.35, 36.87, 35.57, 31.81, 31.76, 31.73, 30.66, 21.10, 19.49, 16.78. HRMS (EI): Exact mass
calculated for C25H32NO [M + H]+: 348.2453, found 348.2449.
(3S,8R,9S,10R,13S,14S)-10,13-Dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-
cyclopenta[a]phenanthren-3-ol (10b). Colourless solid (62 mg, 89%). Purified by column chromatography
on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.21 (50% ethyl acetate in heptane). 1H
NMR (400 MHz, CDCl3) δ 8.61 (d, J = 2.5 Hz, 1H), 8.45 (dd, J = 4.8, 1.7 Hz, 1H), 7.64 (dt, J = 7.9, 1.9 Hz,
1H), 7.25–7.17 (m, 1H), 5.99 (dd, J = 3.3, 1.8 Hz, 1H), 5.52–5.27 (m, 1H), 3.60–3.48 (m, 1H), 2.38–2.20 (m,
3H), 2.15–2.00 (m, 3H), 1.90–1.41 (m, 9H), 1.15–1.01 (m, 8H). 13C NMR (101 MHz, CDCl3) δ 151.81,
147.95, 147.85, 141.34, 133.90, 133.17, 129.42, 123.18, 121.42, 71.79, 57.71, 50.53, 47.50, 42.47, 37.34, 36.85,
35.42, 31.96, 31.79, 31.67, 30.61, 21.03, 19.48, 16.72. HRMS (EI): Exact mass calculated for C24H31NO
[M + H]+: 349.2406, found 349.2411.
(3S,8R,9S,10R,13S,14S)-17-(5-Chloropyridin-3-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-
1H-cyclopenta[a]phenanthren-3-ol (10c). Colorless solid (56 mg, 73%). Purified by column
chromatography on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.48 (50% ethyl acetate
in heptane). 1H NMR (400 MHz, CDCl3) δ 8.49 (d, J = 1.9 Hz, 1H), 8.42 (d, J = 2.3 Hz, 1H), 7.64 (t,
J = 2.1 Hz, 1H), 6.05 (dd, J = 3.3, 1.8 Hz, 1H), 5.39 (d, J = 5.2 Hz, 1H), 3.76–3.45 (m, 1H), 2.38–2.21 (m,
3H), 2.13–1.99 (m, 3H), 1.89–1.81 (m, 2H), 1.81–1.42 (m, 8H), 1.15–1.08 (m, 1H), 1.07 (s, 3H), 1.04 (s, 3H).
13C NMR (101 MHz, CDCl3) δ 150.39, 146.43, 145.50, 141.15, 134.21, 133.40, 131.63, 130.95, 121.25, 71.67,
57.53, 50.30, 47.39, 42.28, 37.16, 36.69, 35.17, 31.88, 31.62, 31.47, 30.41, 20.84, 19.34, 16.60. HRMS (EI):
Exact mass calculated for C24H30ClNO [M + H]+: 383.2016, found 383.2014.
(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-4-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-
cyclopenta[a]phenanthren-3-ol (10d). Colorless solid (62 mg, 88%). Purified by column chromatography
on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.17 (50% ethyl acetate in heptane).1H
NMR (400 MHz, CDCl3) δ 8.50 (d, J = 5.0 Hz, 2H), 7.26 (dd, J = 4.6, 1.6 Hz, 2H), 6.18 (dd, J = 3.3, 1.8 Hz,
1H), 5.42–5.36 (m, 1H), 3.61–3.47 (m, 1H), 2.38–2.20 (m, 3H), 2.17–2.00 (m, 3H), 1.90–1.40 (m, 9H),
1.17–1.00 (m, 8H). 13C NMR (101 MHz, CDCl3) δ 152.61, 149.57, 144.94, 141.34, 131.83, 121.39, 121.36,
71.82, 57.71, 50.50, 47.31, 42.46, 37.33, 36.85, 35.31, 32.00, 31.79, 31.64, 30.54, 21.01, 19.49, 16.77. HRMS
(EI): Exact mass calculated for C24H31NO [M + H]+: 349.2406, found 349.2405.
(3S,8R,9S,10R,13S,14S)-17-(2-Chloropyridin-4-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-
1H-cyclopenta[a]phenanthren-3-ol (10e). Colorless solid (50 mg, 65%). Purified by column
chromatography on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.58 (50% ethyl acetate
in heptane). 1H NMR (400 MHz, CDCl3) δ 8.27 (d, J = 5.2 Hz, 1H), 7.29 (d, J = 1.4 Hz, 1H), 7.18 (dd,
J = 5.2, 1.5 Hz, 1H), 6.22 (dd, J = 3.3, 1.9 Hz, 1H), 5.39 (dt, J = 5.2, 2.0 Hz, 1H), 3.54 (tt, J = 11.3, 4.6 Hz,
1H), 2.39–2.20 (m, 3H), 2.14–2.00 (m, 3H), 1.90–1.81 (m, 2H), 1.80–1.39 (m, 8H), 1.17–1.01 (m, 7H). 13C
NMR (101 MHz, CDCl3) δ 151.65, 151.47, 149.31, 147.79, 141.16, 133.17, 121.33, 121.20, 119.92, 71.66,
57.51, 50.27, 47.20, 42.27, 37.15, 36.68, 35.04, 31.91, 31.61, 31.44, 30.34, 20.81, 19.33, 16.62. HRMS (EI):
Exact mass calculated for C24H30ClNO [M + H]+: 383.2016, found 383.2012.
(3S,8R,9S,10R,13S,14S)-10,13-Dimethyl-17-(1H-pyrazol-4-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-
cyclopenta[a]phenanthren-3-ol (10f). Colorless solid (28 mg, 41%). Purified by column chromatography
on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.16 (50% ethyl acetate in heptane). 1H
NMR (400 MHz, DMSO) δ 12.69 (s, 1H), 7.66 (s, 2H), 5.76 (dd, J = 3.1, 1.7 Hz, 1H), 5.50–5.10 (m, 1H),
4.59 (d, J = 4.5 Hz, 1H), 3.28–3.14 (m, 1H), 2.23–2.05 (m, 4H), 2.05–1.88 (m, 2H), 1.83–1.29 (m, 9H),
1.06–0.94 (m, 5H), 0.90 (s, 3H). 13C NMR (101 MHz, DMSO) δ 145.95, 141.57, 121.66, 120.26, 116.06,
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69.98, 56.61, 50.08, 46.33, 42.25, 40.15, 36.83, 36.27, 34.72, 31.41, 31.03, 30.90, 29.96, 20.53, 19.06, 15.92.
HRMS (EI): Exact mass calculated for C22H30N2O [M + H]+: 338.2358, found 338.2367.
(3S,8R,9S,10R,13S,14S)-17-(Isoquinolin-4-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-
cyclopenta[a]phenanthren-3-ol (10g). Colorless solid (64 mg, 80%). Purified by column chromatography
on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.27 (50% ethyl acetate in heptane). 1H
NMR (400 MHz, CDCl3) δ 9.16 (d, J = 0.9 Hz, 1H), 8.33 (s, 1H), 8.03 (dd, J = 8.5, 1.1 Hz, 1H), 7.97 (dt,
J = 8.0, 1.1 Hz, 1H), 7.73–7.63 (m, 1H), 7.65–7.55 (m, 1H), 5.87 (dd, J = 3.1, 1.6 Hz, 1H), 5.50–5.34 (m, 1H),
3.68–3.42 (m, 1H), 2.48–2.37 (m, 1H), 2.40–2.18 (m, 3H), 2.19–2.09 (m, 1H), 1.90–1.71 (m, 5H), 1.63–1.43
(m, 5H), 1.17–1.03 (m, 5H), 1.01 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 151.16, 149.65, 141.48, 141.38,
135.81, 132.05, 130.31, 129.54, 128.58, 127.87, 127.18, 125.69, 121.49, 71.87, 57.65, 50.78, 49.75, 42.48,
37.37, 36.94, 35.24, 32.62, 31.86, 31.81, 31.07, 21.01, 19.50, 16.42. HRMS (EI): Exact mass calculated for
C28H33NO [M + H]+: 399.2562, found 399.2561.
(3S,8R,9S,10R,13S,14S)-17-(Isoquinolin-5-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-
cyclopenta[a]phenanthren-3-ol (10h). Colorless solid (62 mg, 77%). Purified by column chromatography
on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.29 (50% ethyl acetate in heptane).
1H NMR (400 MHz, CDCl3) δ 9.21 (s, 1H), 8.47 (d, J = 5.9 Hz, 1H), 7.90–7.81 (m, 2H), 7.59–7.53 (m,
1H), 7.48 (dd, J = 7.2, 1.3 Hz, 1H), 5.79 (dd, J = 3.1, 1.6 Hz, 1H), 5.55–5.24 (m, 1H), 3.77–3.36 (m, 1H),
2.45–2.07 (m, 5H), 1.89–1.68 (m, 5H), 1.62–1.43 (m, 5H), 1.16–1.03 (m, 5H), 0.99 (s, 3H). 13C NMR (101
MHz, CDCl3) δ 152.66, 151.24, 142.88, 141.39, 135.54, 135.15, 130.95, 129.61, 129.11, 126.63, 126.44,
121.40, 119.35, 71.72, 57.64, 50.74, 49.62, 42.46, 37.34, 36.90, 35.24, 32.47, 31.82, 31.76, 30.99, 20.96, 19.47,
16.46. HRMS (EI): Exact mass calculated for C28H33NO [M + H]+: 399.2562, found 399.2561.
(3S,8R,9S,10R,13S,14S)-17-(Isoquinolin-6-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-
cyclopenta[a]phenanthren-3-ol (10i). Colorless solid (52 mg, 87%). Purified by column chromatography
on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.24 (50% ethyl acetate in heptane). 1H
NMR (400 MHz, CDCl3) δ 9.19 (s, 1H), 8.49 (d, J = 5.8 Hz, 1H), 7.88 (dd, J = 8.4, 0.9 Hz, 1H), 7.80–7.74
(m, 1H), 7.66 (dd, J = 8.6, 1.6 Hz, 1H), 7.64–7.57 (m, 1H), 6.16 (dd, J = 3.3, 1.8 Hz, 1H), 5.44–5.37 (m, 1H),
3.62–3.48 (m, 1H), 2.38–2.24 (m, 3H), 2.21 (dt, J = 12.2, 3.6 Hz, 1H), 2.17–2.04 (m, 2H), 1.92–1.45 (m, 9H),
1.15 (s, 5H), 1.09 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 154.26, 152.07, 143.22, 141.32, 139.49, 136.13,
130.53, 127.72, 127.42, 127.30, 123.05, 121.50, 120.77, 71.86, 57.88, 50.55, 47.61, 42.48, 37.35, 36.87, 35.62,
32.05, 31.81, 31.70, 30.65, 21.12, 19.51, 16.89. HRMS (EI): Exact mass calculated for C28H33NO [M + H]+:
399.2562, found 399.2563.
(3S,8R,9S,10R,13S,14S)-17-(Isoquinolin-7-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-
cyclopenta[a]phenanthren-3-ol (10j). Colorless solid (50 mg, 83%). Purified by column chromatography
on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.26 (50% ethyl acetate in heptane). 1H
NMR (400 MHz, DMSO) δ 9.32 (s, 1H), 8.44 (d, J = 5.6 Hz, 1H), 8.08 (d, J = 1.8 Hz, 1H), 7.93–7.82 (m,
2H), 7.81–7.72 (m, 1H), 6.33–6.15 (m, 1H), 5.41–5.21 (m, 1H), 4.60 (d, J = 4.5 Hz, 1H), 3.29–3.22 (m,
1H), 2.36–1.99 (m, 6H), 1.85–1.50 (m, 7H), 1.49–1.32 (m, 2H), 1.14 (s, 3H), 1.06–0.95 (m, 5H). 13C NMR
(101 MHz, DMSO) δ 153.18, 152.54, 142.61, 141.61, 135.26, 134.05, 129.80, 129.13, 128.36, 126.36, 123.32,
120.23, 119.90, 69.98, 57.21, 49.84, 46.67, 42.24, 36.83, 36.26, 34.66, 31.40, 31.27, 30.96, 29.97, 20.52, 19.06,
16.27. HRMS (EI): Exact mass calculated for C28H33NO [M + H]+: 399.2562, found 399.2561.
(3S,8R,9S,10R,13S,14S)-17-(1H-indol-4-yl)-10,13-Dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-
cyclopenta[a]phenanthren-3-ol (10k). Colorless solid (60 mg, 78%). Purified by column chromatography
on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.21 (50% ethyl acetate in heptane). 1H
NMR (400 MHz, DMSO) δ 11.05 (s, 1H), 7.32–7.21 (m, 2H), 7.02 (t, J = 7.7 Hz, 1H), 6.90 (dd, J = 7.4,
1.0 Hz, 1H), 6.49–6.43 (m, 1H), 5.96 (dd, J = 3.1, 1.7 Hz, 1H), 5.33 (d, J = 5.1 Hz, 1H), 4.59 (d, J = 4.5 Hz,
1H), 3.30–3.22 (m, 1H), 2.34–2.26 (m, 1H), 2.23–2.00 (m, 4H), 1.95–1.88 (m, 1H), 1.80–1.29 (m, 9H), 1.02
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(d, J = 9.7 Hz, 8H). 13C NMR (101 MHz, DMSO) δ 153.28, 141.59, 136.06, 128.78, 127.49, 126.77, 124.76,
120.40, 120.30, 116.87, 110.07, 101.27, 69.98, 57.00, 50.07, 47.71, 42.26, 36.86, 36.30, 35.08, 31.54, 31.42,
31.10, 30.18, 20.51, 19.09, 16.69. HRMS (EI): Exact mass calculated for C27H33NO [M + H]+: 387.2562,
found 387.2562.
(3S,8R,9S,10R,13S,14S)-17-(1H-Indol-5-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-
cyclopenta[a]phenanthren-3-ol (10l). Colorless solid (56 mg, 72%). Purified by column chromatography
on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.18 (50% ethyl acetate in heptane). 1H
NMR (400 MHz, DMSO) δ 11.00 (s, 1H), 7.52 (d, J = 1.9 Hz, 1H), 7.37–7.25 (m, 2H), 7.13 (dd, J = 8.4,
1.7 Hz, 1H), 6.45–6.34 (m, 1H), 5.81 (dd, J = 3.0, 1.6 Hz, 1H), 5.32 (d, J = 4.8 Hz, 1H), 4.65–4.53 (m, 1H),
3.29–3.22 (m, 1H), 2.23–2.10 (m, 4H), 2.06–1.94 (m, 2H), 1.82–1.30 (m, 9H), 1.08–0.95 (m, 8H). 13C NMR
(101 MHz, DMSO) δ 155.31, 141.58, 134.96, 127.51, 125.38, 123.98, 120.37, 120.27, 117.46, 111.05, 101.28,
69.98, 57.30, 49.95, 46.64, 42.25, 36.84, 36.26, 35.17, 31.40, 31.03, 31.00, 30.07, 20.53, 19.06, 16.50. HRMS
(EI): Exact mass calculated for C27H33NO [M + H]+: 387.2562, found 387.2563.
(3S,8R,9S,10R,13S,14S)-17-(1H-Indol-6-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-
cyclopenta[a]phenanthren-3-ol (10m). Colorless solid (53 mg, 69%). Purified by column chromatography
on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.25 (50% ethyl acetate in heptane).
1H NMR (400 MHz, DMSO) δ 10.91 (s, 1H), 7.41 (d, J = 8.3 Hz, 1H), 7.35 (s, 1H), 7.26 (t, J = 2.7 Hz,
1H), 7.02 (dd, J = 8.3, 1.5 Hz, 1H), 6.45–6.17 (m, 1H), 5.92–5.73 (m, 1H), 5.42–5.12 (m, 1H), 4.54 (s, 1H),
3.26–3.18 (m, 1H), 2.21–2.06 (m, 4H), 2.03–1.93 (m, 2H), 1.79–1.26 (m, 9H), 1.06–0.91 (m, 8H). 13C NMR
(101 MHz, DMSO) δ 155.05, 141.59, 135.93, 129.50, 126.49, 125.45, 124.72, 120.27, 119.59, 118.25, 108.80,
100.85, 69.98, 57.27, 49.93, 46.67, 42.25, 36.84, 36.27, 35.21, 31.41, 31.03, 30.06, 20.53, 19.07, 16.54. HRMS
(EI): Exact mass calculated for C27H33NO [M + H]+: 387.2562, found 387.2563.
3.2. Biological Evaluation
3.2.1. Cell Studies
Human cervical carcinoma (HeLa) cells were seeded in 96-well plates at 15,000 cells/well in the
presence of 5-fold dilutions of the compounds. After 3 days of incubation, the cells were trypsinized
and counted by means of a Coulter counter (Analis, Leuven, Belgium). Human dermal microvascular
endothelial (HMEC-1) cells were seeded on gelatin- coated 48-well plates at 20,000 cells/well. After
overnight incubation, 5-fold dilutions of the compounds were added. Three days later, the cells
were trypsinized and counted. Human T-cell leukemia (CEM) cells were seeded in 96-well plates at
60,000 cells/well in the presence of the compounds, allowed to proliferate for 4 days and then counted.
The 50% inhibitory concentration (IC50) was defined as the compound concentration required to reduce
cell proliferation by 50% [18].
3.2.2. Protein Kinase Assay
For the CDK8 profiling we used a kinase selectivity and profiling assay (DiscoveRx) [19]. The assay
uses kinase-tagged T7 phage strains which were grown in parallel in 24-well blocks in an Escherichia coli
host derived from the BL21 strain. E. coli were grown to log-phase and infected with T7 phage from a
frozen stock (multiplicity of infection = 0.4) and incubated with shaking at 32 ◦C until lysis (90–150 min).
The lysates were centrifuged (6000× g) and filtered (0.2 µm) to remove cell debris. Streptavidin-coated
magnetic beads were treated with biotinylated small molecule ligands for 30 min at room temperature
to generate affinity resins for kinase assays. The liganded beads were blocked with excess biotin and
washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove
unbound ligand and to reduce non-specific phage binding. Binding reactions were assembled by
combining kinases, liganded affinity beads, and test compounds in 1× binding buffer (20% SeaBlock,
0.17× PBS, 0.05% Tween 20, 6 mM DTT). Test compounds were prepared as 40× stocks in 100% DMSO
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and directly diluted into the assay. All reactions were performed in polypropylene 384-well plates
in a final volume of 20 µL. The assay plates were incubated at room temperature with shaking for
1 h and the affinity beads were washed with wash buffer (1× PBS, 0.05% Tween 20). The beads
were then re-suspended in elution buffer (1× PBS, 0.05% Tween 20, 0.5 µM non-biotinylated affinity
ligand) and incubated at room temperature with shaking for 30 min. The kinase concentration in the
eluates was measured by qPCR. The test compounds were screened at 50 nM, and results for primary
screen binding interactions are reported as POC (percent of control). The negative control consists of
adding an equal DMSO volume without a test compound and the positive control consist of a control
compound. From this POC is calculated: ((test compound signal–positive control signal)/(negative
control signal–positive control signal)) × 100%. Negative control = DMSO (100% Ctrl); Positive control
= control compound (0% Ctrl), where lower numbers indicate stronger hits in the matrix.
4. Conclusions
Structure-activity relationship (SAR) studies have revealed that steroidal analogs of cortistatin A
to act as novel leads for further anti-cancer drug development mediated by inhibition of CDK8 [7,8,20].
In total, 13 new analogs of cortistatin A 4 have been prepared using the Suzuki–Miyaura reaction. All
analogs were evaluated for their cytotoxic effects. Additionally, some of the analogs were evaluated
for their ability to inhibit CDK8 at 50 nM concentration. The most cytotoxic compounds proved to be
compounds 10i, j and l, with either a 6- or 7-isoquinoline attached in the 17 position of the steroidal
nucleus This is in accordance with previous literature based on 3-amminosteroids [7,17]. However, the
compounds proved less potent than the included standard 2-ME 2. One exception was compound
10l, which exhibited an IC50-value of 0.59 µM towards the HMEC-1 cell line. The compound has a
5-indol ring attached to the 17-position of the steroidal core. No correlation between the ability to
inhibit CDK8 and the cytotoxicity was observed, as the most prominent CDK8 inhibitor proved to be
compound 10h, with a 5-isoquinoline sidechain attached. Hence, the mechanism behind the toxicity of
these compounds cannot be related to inhibition of these enzymes.
Supplementary Materials: The following are available online, Protocols for the preparation, physical and spectral
data of the intermediates 7, 8 and 9a–9m.
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